Subcutaneous Administration of Interleukin‐2 in Human Immunodeficiency Virus Type 1—Infected Persons | Zendy

Richard T. Davey | Zendy; Doreen Chaitt | Zendy; Stephen C. Piscitelli | Zendy; Mary Wells | Zendy; Joseph A. Kovacs | Zendy; Robert Walker | Zendy; Judith Falloon | Zendy; Michael A. Polis | Zendy; Julia A. Metcalf | Zendy; Henry Masur | Zendy; G. Fyfe | Zendy; H. Clifford Lane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Subcutaneous Administration of Interleukin‐2 in Human Immunodeficiency Virus Type 1—Infected Persons

Author(s) -

Richard T. Davey,

Doreen Chaitt,

Stephen C. Piscitelli,

Mary Wells,

Joseph A. Kovacs,

Robert Walker,

Judith Falloon,

Michael A. Polis,

Julia A. Metcalf,

Henry Masur,

G. Fyfe,

H. Clifford Lane

Publication year - 1997

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/513971

Subject(s) - medicine , toxicity , immunology , interleukin 2 , viral load , virus , subcutaneous injection , immunopathology , interleukin , adverse effect , gastroenterology , virology , cytokine

The safety and efficacy were assessed of 5-day cycles of subcutaneous (sc) interleukin-2 (IL-2) every 8 weeks in human immunodeficiency virus type 1-infected outpatients with >200 CD4 cells/mm3. Immunologic, virologic, and toxicity parameters were measured in 18 patients receiving standard antiretrovirals plus 5-day courses of sc IL-2 (3-18 MIU/day) every 2 months. Systemic toxicities established the maximally tolerated dose (MTD) of IL-2 as 15 MIU/day. CD4 cell responses appeared to correlate directly with baseline CD4 cell counts, with several patients experiencing a dramatic rise after 3 cycles. Virus load increased only transiently in the peri-injection period. It was concluded that serial cycles of outpatient sc IL-2 can be administered safely, with an MTD of 15 MIU/day. Patients with higher baseline counts appear to have a greater CD4 cell response to sc IL-2 therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research